SCHEMBL3274401

SCHEMBL3274401

NC(=O)c1ccc(S(=O)(=O)Nc2ccccc2Oc2ccccc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.72
PTGDR2 Q9Y5Y4 2/20 0.58
CACNA1H O95180 1/20 0.55
CACNA1B Q00975 1/20 0.55
CCR1 P32246 1/20 0.54
CCR2 P41597 1/20 0.54
TDP1 Q9NUW8 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.53
PARP10 Q53GL7 2/20 0.53
MRGPRX1 Q96LB2 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
ACLY P53396 1/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2897956 0.89 CCR1 (0.60) POLBPTGDR2CACNA1HCACNA1BCCR1
SCHEMBL4043636 0.87 PTGDR2 (0.57) POLBPTGDR2CACNA1HCACNA1BCCR1
SCHEMBL3049525 0.85 CACNA1H (0.56) POLBPTGDR2CACNA1HCACNA1BCCR1
SCHEMBL3049521 0.85 POLB (0.53) POLBPTGDR2CACNA1HCACNA1BCCR1
SCHEMBL5458136 0.84 POLB (1.00) POLBL3MBTL1SMN1; SMN2KDM4EALDH1A1
SCHEMBL3050790 0.82 PTPN1 (0.61) CACNA1HCACNA1BCCR1CCR2TDP1
SCHEMBL3047854 0.82 PTGDR2 (0.57) POLBPTGDR2CACNA1HCACNA1BCCR1
SCHEMBL3757218 0.81 POLB (0.55) POLBPTGDR2CACNA1HCACNA1BCCR1
SCHEMBL3148243 0.81 CCR2 (0.70) CCR1CCR2
SCHEMBL3054749 0.81 CCR1 (0.54) POLBPTGDR2CACNA1HCACNA1BCCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481527-B2 Benzamide derivatives as bradykinin antagonists RICHTER GEDEON NYRT. (HU) 2013-07-09 US disclosed
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-04-08 US disclosed
EP-2076491-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-07-08 EP disclosed
WO-2008068540-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087423-A1 NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, HRH1 POLB 3375/4885PTGDR2 195/4885CACNA1H 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.